Abstract
In this chapter, we examine whether the 2013 DPCO has been successful in making essential medicines more affordable. Before we do so, it is useful to recall historical assessments of previous versions of the DPCO. Historical accounts indicate that the implementation of DPCO regulations in India has been ineffective. In the 1970s, the implementation of the recommendations of the Hathi Committee were delayed by 4 years. Although the committee established the importance of focusing price regulation based on the ‘essentiality’ of drugs rather than their prices, the recommendation was forgotten by 2002, leading to a fresh debate on the issue. In 1979, the control of drug prices led to a troubling shortage of essential drugs, causing hardships for patients (Basak 2008). The drafting of the drug policy was delayed in the 1980s due to opposition from industry associations (EPW 1985). In 1986, the pharmaceutical policy was still unclear about what drugs needed to be brought under price regulation, allowing industry associations to influence regulators on behalf of the pharmaceutical firms (Bal 1986a, b). In 1990, the industry and trade associations warned about a possible nationwide strike unless the implementation of price control was postponed (EPW 1990). Similarly, after the implementation of the 1995 price control regime, prices of essential medicines rose, which benefited pharmaceutical producers (Malhotra 2010; Rane 1996). Before we examine the effectiveness of the 2013 DPCO, we discuss the assessment by the NPPA as well as an assessment by the pharmaceutical industry lobby in collaboration with IMS.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Table 6.2 also reveals a significant limitation of the 2013 DPCO. While it controls the price of plain medicines, its combinations are excluded from regulation. Also, several larger, often-prescribed medicines within the same 3-digit therapeutic category are excluded. Overall, the use of relatively smaller, and insignificant medicines for comparison cannot be described as a strength of the IMS study design.
References
Bal, A. (1986a). Distortions in drug policy: Who is to be blamed? Economic and Political Weekly, 21(23), 1029–1032.
Bal, A. (1986b). Drug Policy. Economic and Political Weekly, 21, 2009–2014.
Basak, S. C. (2008). The genesis of drug price control. PharmaBiz [online]. Available from http://pharmabiz.com/ArticleDetails.aspx?aid=42905&sid=9
Bhaumik, S. (2013). India’s health ministry bans pioglitazone, metamizole, and flupentixol-melitracen. British Medical Journal, 347, f4366.
Business Standard. (2014, March 19). Govt lifts ban on painkiller Analgin. Available online http://www.business-standard.com/article/companies/govt-lifts-ban-on-painkiller-analgin-114031900803_1.html
DPCO. (2013, May 15). Drug price control order 2013. The Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii). Ministry of Chemicals and Fertilizers, Government of India.
EPW. (1985). Drug policy in limbo. Economic and Political Weekly, 20, 772–774.
EPW. (1990). Towards a drug policy? Economic and Political Weekly, 25, 1919–1920.
IMS Health. (2015). Assessing the impact of price control measures on access to medicines in India. IMS Health India Report.
Malhotra, P. (2010). The impact of TRIPS on India: An access to medicines perspective. London: Palgrave Macmillan.
Nautiyal, S. (2014a, September 25). Pharma cos have to comply with NPPA’s July 10 order although guidelines stands withdrawn. PharmaBiz.com
Nautiyal, S. (2014b, September 12). Cipla, Pfizer, Sanofi cut prices of diabetic, cardiac drugs as per NPPA order on July 10. PharmaBiz.com
Nautiyal, S. (2014c, July 24). Pharma cos refuse to cut prices of 108 products despite NPPA order on July 10. PharmaBiz.com
NPPA. (2017). Compliance with DPCO 1995 and DPCO 2013. Available online http://www.nppaindia.nic.in/order/stmt-14-03-2017.pdf
PharmaBiz. (2015). Price control unlikely to improve access to medicines in India: IMS study. PharmaBiz [online]. Available from http://pharmabiz.com/NewsDetails.aspx?aid=89417&sid=2
Rane, W. (1996, August 24–31). Analysis of drug prices, 1980–1995. Economic and Political Weekly, 31, 2331–2340.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Bhaskarabhatla, A. (2018). How Effective Are the 2013 DPCO Regulations?. In: Regulating Pharmaceutical Prices in India. India Studies in Business and Economics. Springer, Cham. https://doi.org/10.1007/978-3-319-93393-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-93393-1_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-93392-4
Online ISBN: 978-3-319-93393-1
eBook Packages: Economics and FinanceEconomics and Finance (R0)